DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE

“预防胜于治疗”，是传染病疫苗背后的动机。目前的流感疫苗需要帮助，因为它们只能在短时间内有效，特别是在老年人和慢性病患者中。此外，必须每年制备新的疫苗，以防止新的流感病毒株。因此，对于开发新的免疫增强佐剂以改进现有的流感疫苗存在大量需求。我们的合同支持开发一种新的疫苗佐剂Fos 47，该佐剂可提高疫苗在动物模型中的耐久性和交叉保护作用。将在流感病毒攻毒模型中评估疫苗佐剂Fos 47的保护效力，以确定最佳剂量、途径和免疫频率。将大规模制备疫苗佐剂，用于启动人体临床试验。

“Prevention is better than cure”, is the motive behind the vaccines for infectious diseases. Current vaccines for influenza need help as they are only effective for short durations, particularly in elderly individuals and patients with chronic diseases. Also, new vaccines must be prepared yearly to protect against new strains of influenza virus. Thus, there is substantial demand for the development of new immune boosting adjuvants to improve existing influenza vaccines. Our contract supports the development of a new vaccine adjuvant, Fos47, that improves vaccines durability and cross-protection in animal models. The protective efficacy of vaccine adjuvant Fos47 will be assessed in influenza virus challenge models to identify an optimal dosage, route and frequency of immunization. The vaccine adjuvant will be prepared in a large scale for the initiation of human clinical trials.